JP Morgan Chase
GYRE icon

JP Morgan Chase’s Gyre Therapeutics GYRE Stock Holding History

JP Morgan Chase’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-853
Closed -$26K – 6769
2021
Q3 		$26K Buy
+853
New +$28.1K ﹤0.01% 5992

Other funds holding GYRE

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase's GYRE Position: Q1 2026 in Review

JP Morgan Chase increased its Gyre Therapeutics (GYRE) stake by 1.3% in Q1 2026, buying an estimated $528 and bringing the position to 5,181 shares worth $35.4K. The position accounts for ﹤0.01% of the portfolio, ranked #6336.

JP Morgan Chase first reported a position in GYRE in Q2 2013 and has held it in 34 quarters since. The position peaked at $1.85M in Q1 2019. 56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.

  • JP Morgan Chase held 5,181 shares of Gyre Therapeutics worth $35.4K as of Q1 2026.
  • JP Morgan Chase bought 68 Gyre Therapeutics shares in Q1 2026, an estimated $528.
  • Gyre Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6336 holding.
  • JP Morgan Chase first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 34 quarters since.
  • JP Morgan Chase's Gyre Therapeutics position peaked at $1.85M in Q1 2019.
  • 56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.